Join        Login             Stock Quote

Perrigo (PRGO) Partner Receives FDA Final Approval of Betamethasone Valerate Foam

 November 27, 2012 02:15 PM

(By Balaseshan) Perrigo Co. (NASDAQ: PRGO) said its partner received U.S. Food and Drug Administration final approval of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam.

Cobrek Pharmaceuticals Inc. received final approval for its Abbreviated New Drug Application (ANDA) for betamethasone valerate foam 0.12%, which is indicated for the relief of corticosteroid-responsive skin conditions of the scalp (scalp psoriasis).

Perrigo has manufactured the product and is preparing to begin commercial shipments on January 15, 2013, consistent with the date certain launch settlement. Cobrek was first to file, making the product eligible for 180 days of marketing exclusivity.

[Related -Japan Surges Near 5-Year Highs]

"This is our sixth product approval using a foam dosage form, which requires specialized development and manufacturing capabilities. It is an example of the excellent partnership we have with Cobrek and we are committed to making quality healthcare more affordable for our customers and drive value for our shareholders," said Joseph Papa, CEO of Perrigo.

Perrigo is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription pharmaceuticals, infant formulas, nutritional products and active pharmaceutical ingredients (API).

The company is the store brand manufacturer of OTC pharmaceutical products and infant formulas. The company has four segments, aligned primarily by type of product: consumer healthcare, nutritionals, prescription pharmaceuticals and API.

[Related -Dividend Roundup: ADM, ATI, EL, FLR, PRGO, TYCO]

PRGO is trading down 0.30 percent at $102.27 on Tuesday. The stock has been trading between $90.18 and $120.78 for the past 52 weeks.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.